NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.61 +0.20 (+2.13 %)
(As of 05/27/2018 11:47 AM ET)
Previous Close$9.61
Today's Range$9.37 - $9.7322
52-Week Range$7.67 - $18.00
Volume670,262 shs
Average Volume585,339 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.42

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LXRX
CUSIP52887210
Phone281-863-3000

Debt

Debt-to-Equity Ratio8.85
Current Ratio2.72
Quick Ratio2.70

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.33 million
Price / Sales11.26
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book38.44

Profitability

EPS (Most Recent Fiscal Year)($1.27)
Net Income$-129,050,000.00
Net Margins-140.09%
Return on Equity-213.32%
Return on Assets-36.99%

Miscellaneous

Employees174
Outstanding Shares105,830,000

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The biopharmaceutical company earned $25.21 million during the quarter, compared to the consensus estimate of $25.30 million. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.32%. The business's revenue was up 37.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.33) EPS. View Lexicon Pharmaceuticals' Earnings History.

What price target have analysts set for LXRX?

6 brokers have issued 12 month price objectives for Lexicon Pharmaceuticals' stock. Their predictions range from $10.00 to $40.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $24.40 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (5/8/2018)
  • 2. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017)
  • 3. Cowen Inc analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)

Who are some of Lexicon Pharmaceuticals' key competitors?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 53)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 58)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 59)

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

News coverage about LXRX stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.06 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.99%), USS Investment Management Ltd (2.59%), Sector Gamma AS (0.81%), Pinnacle Associates Ltd. (0.75%), Northern Trust Corp (0.54%) and Schwab Charles Investment Management Inc. (0.21%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Which major investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, BlackRock Inc., Pinnacle Associates Ltd., DekaBank Deutsche Girozentrale, New York State Common Retirement Fund, GSA Capital Partners LLP, Northern Trust Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Which major investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was purchased by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, UBS Group AG, Victory Capital Management Inc., Cim Investment Mangement Inc., A.R.T. Advisors LLC, Virginia Retirement Systems ET AL, Trexquant Investment LP and Sector Gamma AS. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $9.61.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $1.02 billion and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.


MarketBeat Community Rating for Lexicon Pharmaceuticals (LXRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Lexicon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.40, suggesting that the stock has a possible upside of 153.90%. The high price target for LXRX is $40.00 and the low price target for LXRX is $10.00. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.202.332.80
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.40$24.50$24.80$28.75
Price Target Upside: 153.90% upside202.84% upside180.23% upside138.99% upside

Lexicon Pharmaceuticals (NASDAQ:LXRX) Consensus Price Target History

Price Target History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018WedbushReiterated RatingOutperform$42.00 ➝ $40.00HighView Rating Details
5/4/2018CitigroupLower Price TargetBuy ➝ Buy$28.00 ➝ $27.00MediumView Rating Details
5/4/2018Stifel NicolausLower Price TargetBuy ➝ Buy$25.00 ➝ $24.00HighView Rating Details
2/23/2018Needham & Company LLCDowngradeBuy ➝ HoldHighView Rating Details
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$15.00 ➝ $10.00HighView Rating Details
8/1/2017CowenReiterated RatingHoldHighView Rating Details
5/3/2017HC WainwrightSet Price TargetBuy$27.00HighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings History and Estimates Chart

Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.20)
2019 EPS Consensus Estimate: ($0.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.25)($0.25)($0.25)
Q1 20191($0.28)($0.28)($0.28)
Q2 20191($0.25)($0.25)($0.25)
Q3 20191($0.13)($0.13)($0.13)
Q4 20191($0.06)($0.06)($0.06)

Lexicon Pharmaceuticals (NASDAQ LXRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.43)($0.40)$25.30 million$25.21 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.43)($0.31)$29.84 million$33.05 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.36)($0.2910)$27.97 million$26.94 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.45)($0.33)$18.34 million$12.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.44)($0.33)$14.81 million$18.29 millionViewN/AView Earnings Details
3/3/2017Q4 2016($0.51)($0.31)$15.56 million$23.00 millionViewN/AView Earnings Details
11/1/2016Q316($0.50)($0.35)$9.68 million$27.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.40)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.44 million$0.57 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.05)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.2380 millionViewListenView Earnings Details
7/30/2013Q2 2013($0.35)($0.42)$0.28 million$0.21 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.35)$0.32 million$0.36 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.2180 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
7/31/2012Q2 2012($0.42)($0.38)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.49)($0.39)ViewN/AView Earnings Details
2/22/2012Q4 2011($0.56)($0.64)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.63)($0.54)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.63)($0.52)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.49)($0.59)ViewN/AView Earnings Details
2/24/2011Q4 2010($0.56)($0.48)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.56)($0.57)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.49)($0.52)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.49)($0.92)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.98)($0.91)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.98)($0.97)ViewN/AView Earnings Details
7/28/2009Q2 2009($1.12)($1.02)ViewN/AView Earnings Details
4/28/2009Q1 2009($0.91)($1.13)ViewN/AView Earnings Details
2/25/2009Q4 2008($1.19)($0.79)ViewN/AView Earnings Details
10/30/2008Q3 2008($1.12)($1.03)ViewN/AView Earnings Details
7/29/2008Q2 2008($1.12)($1.02)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.84)($0.92)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.91)($0.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Lexicon Pharmaceuticals (NASDAQ:LXRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2018Alexander A SantiniEVPBuy745$9.78$7,286.105,297View SEC Filing  
11/17/2017Public Equities L.P. InvusDirectorBuy180,727$10.11$1,827,149.97View SEC Filing  
11/15/2017Lonnel CoatsCEOBuy10,000$9.91$99,100.0042,985View SEC Filing  
11/14/2017Jeffrey L WadeEVPBuy2,000$9.48$18,960.0050,597View SEC Filing  
11/14/2017Public Equities L.P. InvusDirectorBuy575,946$9.64$5,552,119.44View SEC Filing  
11/10/2017Public Equities L.P. InvusDirectorBuy145,680$9.74$1,418,923.20View SEC Filing  
9/15/2017Lonnel CoatsInsiderBuy30,000$12.54$376,200.00View SEC Filing  
9/15/2017Sam L BarkerDirectorBuy1,000$12.50$12,500.0025,623View SEC Filing  
6/6/2016James F TessmerVPSell1,500$15.00$22,500.0017,446View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.0021,946View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/25/2013Bryan A KleinleinCFOSell227,626$0.13$29,591.38View SEC Filing  
10/9/2013Bryan A KleinleinCFOSell83,281$0.19$15,823.39View SEC Filing  
7/9/2013Bryan A KleinleinCFOSell88,235$0.11$9,705.85View SEC Filing  
6/27/2013Alexander Richard WalshCEOSell160,000$0.13$20,800.00View SEC Filing  
6/18/2013Alexander Richard WalshCEOSell220,000$0.18$39,600.00View SEC Filing  
6/7/2013Alexander Richard WalshCEOSell170,000$0.19$32,300.00View SEC Filing  
11/21/2012Alexander Richard WalshCEOSell23,700$0.34$8,058.00View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
10/3/2012Alexander Richard WalshCEOSell25,000$0.30$7,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Lexicon Pharmaceuticals (NASDAQ LXRX) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) Will Announce Quarterly Sales of $16.64 MillionZacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) Will Announce Quarterly Sales of $16.64 Million
www.americanbankingnews.com - May 26 at 2:36 AM
 Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Earnings of -$0.35 Per Share Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 24 at 3:18 PM
Lexicon Pharmaceuticals (LXRX) Outperform Rating Reaffirmed at WedbushLexicon Pharmaceuticals' (LXRX) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - May 22 at 5:25 PM
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetesFDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
finance.yahoo.com - May 22 at 8:16 AM
Lexicon Pharmaceuticals (LXRX) Upgraded at BidaskClubLexicon Pharmaceuticals (LXRX) Upgraded at BidaskClub
www.americanbankingnews.com - May 17 at 5:47 PM
Lexicon Pharmaceuticals (LXRX) Given Consensus Rating of "Hold" by AnalystsLexicon Pharmaceuticals (LXRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 13 at 3:33 AM
Lexicon Pharmaceuticals (LXRX) to Post Q2 2018 Earnings of ($0.29) Per Share, Wedbush ForecastsLexicon Pharmaceuticals (LXRX) to Post Q2 2018 Earnings of ($0.29) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 10 at 7:04 AM
Lexicon Pharmaceuticals (LXRX) Forecasted to Earn Q1 2019 Earnings of ($0.28) Per ShareLexicon Pharmaceuticals (LXRX) Forecasted to Earn Q1 2019 Earnings of ($0.28) Per Share
www.americanbankingnews.com - May 9 at 9:06 AM
 Brokerages Expect Lexicon Pharmaceuticals (LXRX) Will Announce Quarterly Sales of $22.38 Million Brokerages Expect Lexicon Pharmaceuticals (LXRX) Will Announce Quarterly Sales of $22.38 Million
www.americanbankingnews.com - May 9 at 4:08 AM
Lexicon Pharmaceuticals (LXRX) Upgraded by Zacks Investment Research to HoldLexicon Pharmaceuticals (LXRX) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 8 at 10:38 AM
Blog Exposure - Lexicon Pharma’s New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical TherapeuticsBlog Exposure - Lexicon Pharma’s New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics
finance.yahoo.com - May 8 at 8:11 AM
 Analysts Anticipate Lexicon Pharmaceuticals (LXRX) to Post -$0.45 Earnings Per Share Analysts Anticipate Lexicon Pharmaceuticals (LXRX) to Post -$0.45 Earnings Per Share
www.americanbankingnews.com - May 7 at 8:06 AM
Citigroup Lowers Lexicon Pharmaceuticals (LXRX) Price Target to $27.00Citigroup Lowers Lexicon Pharmaceuticals (LXRX) Price Target to $27.00
www.americanbankingnews.com - May 5 at 2:59 AM
BidaskClub Upgrades Lexicon Pharmaceuticals (LXRX) to HoldBidaskClub Upgrades Lexicon Pharmaceuticals (LXRX) to Hold
www.americanbankingnews.com - May 5 at 12:29 AM
Lexicon Pharmaceuticals (LXRX) Posts  Earnings Results, Beats Expectations By $0.03 EPSLexicon Pharmaceuticals (LXRX) Posts Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 4 at 9:33 PM
Lexicon Pharmaceuticals (LXRX) Price Target Lowered to $24.00 at Stifel NicolausLexicon Pharmaceuticals (LXRX) Price Target Lowered to $24.00 at Stifel Nicolaus
www.americanbankingnews.com - May 4 at 6:11 PM
Lexicon Pharma (LXRX) Announces Publication of New XERMELO Data in Clinical TherapeuticsLexicon Pharma (LXRX) Announces Publication of New XERMELO Data in Clinical Therapeutics
www.streetinsider.com - May 4 at 5:39 PM
Lexicon Pharma Q1 revenues up 38%Lexicon Pharma Q1 revenues up 38%
seekingalpha.com - May 4 at 8:14 AM
Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical TherapeuticsLexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical Therapeutics
finance.yahoo.com - May 4 at 8:14 AM
Edited Transcript of LXRX earnings conference call or presentation 3-May-18 12:00pm GMTEdited Transcript of LXRX earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 8:14 AM
BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40
www.reuters.com - May 3 at 5:29 PM
Lexicon Pharmaceuticals (LXRX) CEO Lonnel Coats on Q1 2018 Results - Earnings Call TranscriptLexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:29 PM
Lexicon Pharmaceuticals beats by $0.03, beats on revenueLexicon Pharmaceuticals beats by $0.03, beats on revenue
seekingalpha.com - May 3 at 8:10 AM
Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business UpdateLexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update
finance.yahoo.com - May 3 at 8:10 AM
Lexicon Pharmaceuticals (LXRX) Stock Rating Lowered by Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 26 at 12:27 PM
Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018
finance.yahoo.com - April 26 at 8:12 AM
Lexicon Pharmaceuticals (LXRX) to Release Earnings on MondayLexicon Pharmaceuticals (LXRX) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 6:52 AM
Lexicon Pharmaceuticals (LXRX) Expected to Announce Quarterly Sales of $20.90 MillionLexicon Pharmaceuticals (LXRX) Expected to Announce Quarterly Sales of $20.90 Million
www.americanbankingnews.com - April 22 at 4:24 AM
3 Top Biotech Stocks to Buy Right Now3 Top Biotech Stocks to Buy Right Now
finance.yahoo.com - April 21 at 8:16 AM
 Analysts Expect Lexicon Pharmaceuticals (LXRX) to Post -$0.45 Earnings Per Share Analysts Expect Lexicon Pharmaceuticals (LXRX) to Post -$0.45 Earnings Per Share
www.americanbankingnews.com - April 20 at 5:24 AM
Lexicon Pharmaceuticals (LXRX) Downgraded to "Sell" at Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 8:31 PM
Q1 2018 EPS Estimates for Lexicon Pharmaceuticals (LXRX) Lowered by WedbushQ1 2018 EPS Estimates for Lexicon Pharmaceuticals (LXRX) Lowered by Wedbush
www.americanbankingnews.com - April 18 at 7:52 AM
Lexicon Pharmaceuticals (LXRX) Given Consensus Rating of "Hold" by BrokeragesLexicon Pharmaceuticals (LXRX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 3:21 AM
Lexicon Pharmaceuticals (LXRX) Upgraded to "Hold" at Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:49 PM
Wedbush Boosts Lexicon Pharmaceuticals (LXRX) Price Target to $40.00Wedbush Boosts Lexicon Pharmaceuticals (LXRX) Price Target to $40.00
www.americanbankingnews.com - April 16 at 8:45 AM
BidaskClub Lowers Lexicon Pharmaceuticals (LXRX) to SellBidaskClub Lowers Lexicon Pharmaceuticals (LXRX) to Sell
www.americanbankingnews.com - April 14 at 10:43 AM
Lexicon Pharmaceuticals (LXRX) Lowered to Sell at BidaskClubLexicon Pharmaceuticals (LXRX) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 14 at 12:17 AM
Lexicon Pharmaceuticals (LXRX) Rating Lowered to Strong Sell at BidaskClubLexicon Pharmaceuticals (LXRX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 10 at 9:26 PM
Lexicon Pharmaceuticals (LXRX) Lowered to "Sell" at Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:32 AM
$22.14 Million in Sales Expected for Lexicon Pharmaceuticals (LXRX) This Quarter$22.14 Million in Sales Expected for Lexicon Pharmaceuticals (LXRX) This Quarter
www.americanbankingnews.com - April 5 at 4:34 AM
 Analysts Anticipate Lexicon Pharmaceuticals (LXRX) Will Announce Earnings of -$0.43 Per Share Analysts Anticipate Lexicon Pharmaceuticals (LXRX) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - April 3 at 9:18 AM
Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018
feeds.benzinga.com - April 3 at 7:51 AM
Lexicon Pharma (LXRX) Announces EMA Acceptance of MAA for Sotagliflozin to Treat Adults With Type 1 DiabetesLexicon Pharma (LXRX) Announces EMA Acceptance of MAA for Sotagliflozin to Treat Adults With Type 1 Diabetes
www.streetinsider.com - March 30 at 8:16 AM
Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 DiabetesLexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes
finance.yahoo.com - March 29 at 8:20 AM
Sanofi: EMA to review sotagliflozin as potential  treatment for type 1 diabetesSanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
feeds.benzinga.com - March 29 at 3:13 AM
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 DiabetesBlog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes
finance.yahoo.com - March 28 at 8:23 AM
Lexicon Pharma (LXRX) Submits NDA to FDA for Sotagliflozin to Treat Adults With Type 1 DiabetesLexicon Pharma (LXRX) Submits NDA to FDA for Sotagliflozin to Treat Adults With Type 1 Diabetes
www.streetinsider.com - March 26 at 5:23 PM
Lexicon Pharmaceuticals (LXRX) Raised to Hold at BidaskClubLexicon Pharmaceuticals (LXRX) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 1:58 PM
Lexicon Pharmaceuticals (LXRX) Lowered to Sell at Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 26 at 12:44 PM
Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 DiabetesLexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes
finance.yahoo.com - March 26 at 8:17 AM

SEC Filings

Lexicon Pharmaceuticals (NASDAQ:LXRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Lexicon Pharmaceuticals (NASDAQ:LXRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Lexicon Pharmaceuticals (NASDAQ LXRX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.